 |
Paladin and Somaxon Announce Filing of New Drug Submission for Silenor®
Feb 22, 2012
|
17.4 KB |
|
| |
MONTREAL & SAN DIEGO--(BUSINESS WIRE)--
Paladin Labs Inc. (TSX:PLB) and Somaxon Pharmaceuticals, Inc. (Nasdaq:
SOMX) today announced that Paladin has filed a New Drug Submission (NDS)
that has been accepted for review by Health Canada for Silenor®
(doxepin) for the treatment and symptomatic relief of insomni...
|
|
Somaxon Pharmaceuticals Hires Financial Advisor to Assist in Seeking Strategic Alternatives
Dec 19, 2011
|
15.7 KB |
|
| |
SAN DIEGO--(BUSINESS WIRE)--
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical
company, today announced that it has hired Stifel Nicolaus Weisel as a
strategic advisor. Stifel will assist the company in identifying and
evaluating various strategies to maximize stockholder value.
...
|
|
Somaxon Pharmaceuticals Reports Third Quarter 2011 Financial Results
Nov 3, 2011
|
29.1 KB |
|
| |
Conference call scheduled today at 8:30 a.m. ET (5:30 a.m. PT);Simultaneous
webcast at http://investors.somaxon.com/eventdetail.cfm
SAN DIEGO--(BUSINESS WIRE)--
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical
company, today announced financial results...
|
|
Somaxon Pharmaceuticals to Report Third Quarter 2011 Results and Conduct Conference Call on Thursday, November 3
Oct 19, 2011
|
10.5 KB |
|
| |
SAN DIEGO--(BUSINESS WIRE)--
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical
company, today announced that it will release its third quarter 2011
financial results on Thursday, November 3, 2011 before the opening of
the U.S. financial markets. The Company will also conduct a conference
...
|
|
Somaxon Pharmaceuticals Announces FDA Feedback on Silenor OTC Regulatory Pathway and Changes to Commercial Team
Oct 3, 2011
|
16.6 KB |
|
| |
SAN DIEGO, CA - October 3, 2011 - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that it recently had a meeting with the U.S. Food & Drug Administration (FDA) relating to the over-the-counter (OTC) development program for Silenor®. In the meeting, which Somaxon attended jointly with...
|
|
Somaxon Pharmaceuticals Reports Second Quarter 2011 Financial Results; Company Announces Access to up to $45 Million in Financing
Aug 2, 2011
|
91.4 KB |
|
| |
SAN DIEGO, CA - August 2, 2011 - Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company, today announced financial results for the quarter ended June 30, 2011. For the second quarter of 2011, Somaxon reported net product sales of $6.2 million, compared to net product sales of $2.3 million in the first quar...
|
|
Somaxon Pharmaceuticals to Report Second Quarter 2011 Results and Conduct Conference Call on Tuesday, August 2
Jul 25, 2011
|
10.3 KB |
|
| |
SAN DIEGO, CA - July 25, 2011 - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that it will release its second quarter 2011 financial results on Tuesday, August 2, 2011 after the closing of the U.S. financial markets. The Company will also conduct a conference call that same afternoon at ...
|
|
Somaxon Completes $5 Million Private Placement of Equity to Paladin Labs Inc.
Jun 13, 2011
|
11.2 KB |
|
| |
SAN DIEGO, CA - June 13, 2011 - Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today said it completed its previously announced private placement to Paladin Labs Inc. of 2,184,769 shares of its common stock on June 11, 2011, for aggregate gross proceeds of US$5 million. The private placement was undertaken in connection with the exclusive c...
|
|
Somaxon and Paladin Announce Silenor® EX-US Collaboration
Jun 8, 2011
|
19.0 KB |
|
| |
SAN DIEGO, CA and MONTREAL, CANADA - June 8, 2011 - Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) and Paladin Labs Inc. (TSX:PLB) today announced that they have entered into an exclusive collaboration under which Paladin will commercialize Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance...
|
|
Somaxon Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
May 31, 2011
|
9.6 KB |
|
| |
SAN DIEGO, CA - May 31, 2011 - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that Richard W. Pascoe, Somaxon's president and chief executive officer will present at the Jefferies 2011 Global Healthcare Conference at The Grand Hyatt Hotel in New York City on Monday, June 6, at 9:00 a.m. E...
|
|
Somaxon Pharmaceuticals Announces Presentation of Silenor® Data at National Medical Meetings
May 17, 2011
|
17.6 KB |
|
| |
SAN DIEGO, CA - May 17, 2011 - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that it will present new analyses of data from the Silenor Phase 3 clinical development program at the American Psychiatric Association (APA) 164th Annual Meeting, the Associated Professional Sleep So...
|
|
Somaxon Pharmaceuticals Reports First Quarter 2011 Financial Results
May 3, 2011
|
74.9 KB |
|
| |
SAN DIEGO, CA -May 3, 2011 - Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011.
"During the first quarter of 2011, we continued to lay the foundation for Silenor's® long-term commercial success by growing Sil...
|
|
Somaxon Pharmaceuticals to Report First Quarter 2011 Results and Conduct Conference Call on Tuesday, May 3
Apr 25, 2011
|
9.8 KB |
|
| |
SAN DIEGO, CA - April 25, 2011 - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that it will release its first quarter 2011 financial results on Tuesday, May 3, 2011 after the closing of the U.S. financial markets. The Company will also conduct a conference call that same afternoon at ...
|
|
Somaxon Pharmaceuticals Announces Issuance of Patent Relating to Pharmacokinetics (Food Effect) of Silenor
Mar 29, 2011
|
14.3 KB |
|
| |
SAN DIEGO, CA - March 29, 2011 - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued U.S. patent no. 7,915,307, entitled "Methods of Improving the Pharmacokinetics of Doxepin." This patent generally relates to dosing Silenor® (doxepin) a...
|
|
Somaxon Reports Financial Results for Full Year and Fourth Quarter Ended December 31, 2010
Mar 3, 2011
|
85.9 KB |
|
| |
SAN DIEGO, CA -March 3, 2011 - Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company, today announced financial results for the full year and fourth quarter ended December 31, 2010.
"During 2010, we achieved our key corporate objectives that allowed us to successfully transition from a development stage ...
|
|
Somaxon Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 28, 2011
|
10.3 KB |
|
| |
SAN DIEGO, CA - February 28, 2011 - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that Richard W. Pascoe, Somaxon's president and chief executive officer is scheduled to present at the following investor conferences:
Monday, March 7, 2011
Cowen and ...
|
|
Somaxon Pharmaceuticals to Report Full Year and Fourth Quarter Ended December 31, 2010 Financial Results and Conduct Conference Call on Thursday, March 3
Feb 23, 2011
|
10.2 KB |
|
| |
SAN DIEGO, CA - February 23, 2011 - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that it will release its full year and fourth quarter ended December 31, 2010 financial results on Thursday, March 3, 2011 after the closing of the U.S. financial markets. Somaxon management will conduct a ...
|
|
Somaxon Pharmaceuticals Receives Notice of Allowance for Patent Application Relating to Pharmacokinetics of Silenor
Feb 22, 2011
|
14.7 KB |
|
| |
SAN DIEGO, CA - February 22, 2011 - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims in U.S. patent application no. 11/781,165. This patent application generally relates to dosin...
|
|
Somaxon Pharmaceuticals Announces
Sales Force Expansion and Obtains $15 Million
Revolving Line of Credit
Feb 8, 2011
|
13.8 KB |
|
| |
SAN DIEGO, CA - February 8, 2011 - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that it has engaged its contract sales force partner Publicis Touchpoint Solutions, Inc. to recruit and deploy for Somaxon an additional 35 sales representatives that will exclusively promote Silenor®...
|
|
Somaxon Pharmaceuticals to Present at the 13th Annual Bio CEO & Investor Conference
Feb 7, 2011
|
9.7 KB |
|
| |
SAN DIEGO, CA - February 07, 2011 - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that Richard W. Pascoe, Somaxon's president and chief executive officer, will present at the 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York City on Monday, Feb...
|
|
|
